Endolytix develops novel therapeutics targeting highly resistant mycobacterial infections that are difficult to treat with current antibiotics. Their approach utilizes targeted drug delivery vehicles to administer bactericidal payloads effectively inside and outside of host macrophages. This strategy overcomes the complex cell envelope defenses that typically block conventional drug access to pathogenic NTM.
Funding
$21.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Nontuberculous mycobacterial (NTM) infections, including the MAC complex and *M. abscessus*, are increasingly prevalent and pose significant treatment challenges due to intrinsic antibiotic resistance. Current treatment options are often ineffective, leaving a large patient population with limited solutions. *Mycobacterium tuberculosis* also presents a persistent global health threat due to antibiotic resistance.
Solution
Endolytix Technology is developing therapeutic methods to combat intrinsic antibiotic resistance in NTM infections and *Mycobacterium tuberculosis*. Their approach focuses on novel targets within the mycobacteria to overcome resistance mechanisms. By addressing the root causes of antibiotic failure, Endolytix aims to provide more effective treatment options for these difficult-to-treat infections. This new therapeutic approach has the potential to improve patient outcomes and reduce the burden of these diseases.
Target Audience
The primary target audience includes individuals diagnosed with NTM infections (MAC complex, *M. abscessus*) and *Mycobacterium tuberculosis*, as well as healthcare providers specializing in infectious diseases and pulmonology.
Features
- Targeting intrinsic antibiotic resistance mechanisms in NTM and *Mycobacterium tuberculosis*.
- Development of novel therapeutic agents.